La cadena de opciones muestra datos clave de las opciones de acciones de RAPT Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para RAPT Therapeutics..

RAPT Therapeutics (NASDAQ:RAPT) Bolsa, Cadena de Opciones

RAPT THERAPEUTICS INC

RAPT Therapeutics

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

ADXN

BYND

CELC

CIIT

DCTH

DGXX

EXEL

FBGL

FCUV

FPAY

NCNA

OLMA

RANI

RAPT

TGHL

VIVK

XRTX

YGMZ

DCTH impulsa el premercado con resultados clínicos positivos del estudio CHOPIN, mientras Beyond Meat y Celcuity lideran las mayores subidas.

Acciones de Delcath Systems (DCTH) suben un 14%; Aquí están 20 acciones que se mueven en el premercado

RAPT Therapeutics Inc

Press Releases

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

Management

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

Health Care

Small Cap

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

Financing

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies

Absci

Astria Therapeutics

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

CareDx

CytomX Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Erasca

Geron

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gyre Therapeutics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Kura Oncology

Lexeo Therapeutics

MeiraGTx Hldgs

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

MapLight Therapeutics, Inc. - Common Stock

MapLight Therapeutics

Myriad Genetics

Prime Medicine

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Replimune Group

Rezolute

Tyra Biosciences

Valneva

Vir Biotechnology

Wells Fargo

HC Wainwright & Co.

Guggenheim

Barclays

Clear Street

Comments

RAPT Therapeutics

RAPT Therapeutics (RAPT) Opciones

RAPT Therapeutics (NASDAQ:RAPT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL